Johnson & Johnson announces updated results from Phase 3 CARTITUDE-4 study

Johnson & Johnson announced updated results from the Phase 3 CARTITUDE-4 study supporting durable treatment-free remissions as early as second line treatment with CARVYKTI. In 80 percent of as-treated patients with relapsed or refractory multiple myeloma, RRMM, and standard-risk cytogenetics who were treated with CARVYKTI as early as first relapse, the disease did not progress and no further treatment was required at 2.5 years. These results add to the body of clinical and real-world experience established across more than 9,000 patients treated with CARVYKTI globally. Additional translational analyses demonstrated that patients receiving CARVYKTI in earlier lines had improved immune fitness, which suggests a correlation with longer progression-free survival. These data were featured in oral presentations at the 2025 American Society of Hematology, ASH, Annual Meeting.